F-Prime Capital

Tenvie Therapeutics is a biotechnology company founded to improve patients' lives with neurological, cardiometabolic, and ophthalmic diseases. The company is focused on developing small molecules targeting brain inflammation, metabolic dysfunction, and lysosomal issues, with a robust pipeline inherited from Denali Therapeutics. Tenvie is progressing a range of therapeutics aimed at addressing neurological, cardiometabolic, and ophthalmic conditions. Its collection of fully owned, highly brain-penetrant, and precisely designed peripherally restricted small molecules targets three main factors of disease: alleviating inflammation, correcting metabolic dysfunction, and rejuvenating lysosomal function.

Laurus Bio specializes in precision fermentation, providing expertise to clients involved in microbial fermentation-based manufacturing and product development. The company focuses on the production of animal-origin-free recombinant proteins, growth factors, and cell-culture media supplements. Their offerings cater to various sectors, including cultured meat, biologics, vaccine development, and regenerative medicine. By developing novel non-animal origin proteins and media components, Laurus Bio aims to enhance safety, consistency, and traceability in the pharmaceutical and bio-manufacturing industries, enabling clients to create greener and more sustainable healthcare products.

Shift Bioscience is focused on using advanced simulation techniques to address the challenges of aging and age-related diseases. The company has developed a high-throughput aging biomarker that facilitates the identification of rejuvenation gene factors through AI-driven cell simulations. By employing deep learning technology, Shift tests extensive gene combinations to discover potential drugs that can reverse aging effects and repair mitochondrial genes. The ultimate goal is to create a single family of drugs capable of treating various diseases associated with aging, thereby promoting sustained health into old age through accessible prescriptions.

Xaira Therapeutics is an integrated biotechnology company focused on revolutionizing drug discovery and development through the application of artificial intelligence. Headquartered in the San Francisco Bay Area, Xaira combines expertise in machine learning, extensive biological and clinical data generation, and robust therapeutic product development. By harnessing advanced AI techniques, the company aims to enhance the understanding of biological processes and improve the effectiveness of therapies. Xaira's approach encompasses all stages of drug discovery, striving to transform how diseases are treated and enabling clients to deliver innovative therapeutic solutions.

Metsera is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and metabolic conditions. The company focuses on advancing a variety of oral and injectable treatment options, including incretin, non-incretin, and combination therapies. These treatments are designed to address multiple therapeutic targets, positioning Metsera to meet the evolving demands of the weight loss treatment landscape. Additionally, Metsera integrates proprietary health technology tools to provide personalized care, enhancing the effectiveness of its therapeutic offerings.

Engrail Therapeutics, Inc. is dedicated to developing and commercializing neuro drugs aimed at treating diseases of the nervous system. Founded in 2019 and based in San Diego, California, the company focuses on creating transformative medicines to alleviate the significant burden of such conditions. One of its key products is ENX-101, a preclinical compound designed to modulate a receptor for GABA, a critical neurotransmitter in the brain. Engrail Therapeutics combines biological insights with clinically meaningful solutions to advance its portfolio of therapies, utilizing a flexible transaction model to efficiently progress its drug candidates from development to commercialization.

Nocion Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, established in 2017. The company focuses on developing novel therapeutics called "nocions," which are designed to treat conditions associated with neurogenic inflammation. These nocions specifically target activated sensory neurons, entering nociceptors through large-pore channels that open in response to stimulation. This mechanism allows for the selective blocking of sodium channels, providing targeted and sustained relief for serious conditions such as cough, itch, pain, and inflammation. By offering an alternative to traditional small molecule anesthetics, Nocion Therapeutics aims to deliver more effective treatment options for patients suffering from these debilitating symptoms.

Comanche Biopharma is a biopharmaceutical company focused on developing an investigational small interfering RNA (siRNA) medicine aimed at treating preterm preeclampsia. The company is committed to ensuring that all women and their babies have access to safe and effective therapies for life-threatening complications during pregnancy. Comanche Biopharma's mission emphasizes the importance of evidence-based and affordable solutions, enabling women to receive cost-effective treatments that address the root causes of preeclampsia.

Genomics PLC, established in 2014 and headquartered in Oxford, UK, specializes in developing algorithms and software solutions that harness the power of genomics. The company focuses on cancer, microbes, and rare diseases, offering solutions that transform healthcare provisions for governments and providers, de-risk drug development for pharmaceutical clients, enhance diagnoses and treatment options for clinicians, and ensure accurate result processing for research labs and genome analysts. By applying advanced analytics to massive genomic and phenotypic datasets, Genomics PLC aims to lead the genomic transformation of healthcare, revealing the human wiring diagram and setting standards for genomic data utilization.

OnCusp Therapeutics is a biopharmaceutical company focused on developing innovative oncology therapies aimed at improving treatments for cancer patients worldwide. Founded by Bing Yuan, Eric Slosberg, and Andy Fu, the company is dedicated to translating cutting-edge research into clinical applications. It specializes in advancing preclinical drug candidates to the clinical proof-of-concept stage, enabling a swift transition into global early clinical development. By prioritizing this process, OnCusp Therapeutics aims to accelerate the innovation of oncology medications, ultimately providing critical support and hope to those affected by cancer.

PlasmaGen Biosciences Pvt. Ltd. is an Indian bio-pharmaceutical company based in Bengaluru, specializing in the manufacture of plasma-derived products and therapies. Established in 2010, the company develops a range of plasma protein therapies, including PlasmaGlob and AlbuMax, which are Normal Human Immunoglobulin formulations for intravenous use. Their product portfolio also includes PlasmaRho-D I.V. for Rho (D) immunization, PlasmaRAB for rabies post-exposure prophylaxis, and PlasmaHep for various hepatitis B-related indications. Additionally, PlasmaGen offers VerBumin for conditions such as hypovolemic shock and plasma exchange dialysis. The company serves a diverse clientele, including clinicians, medical practitioners, corporate hospitals, and government institutions, positioning itself as a key provider of plasma products across various medical fields, including hematology, oncology, and immunology.

T-Therapeutics is a biopharmaceutical company specializing in the development of engineered soluble biologics for oncological and immunological conditions. The company utilizes a proprietary T cell receptor (TCR) discovery platform, which is based on a highly humanized mouse model. This innovative approach allows T-Therapeutics to identify TCRs that target human antigens not obtainable from human samples. The TCRs bind specific pMHC targets on target cells, facilitating the recruitment of T cells to either attack cancer cells or modulate immune responses. By leveraging advanced techniques in mouse genome engineering, single cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance treatment options for patients suffering from chronic and infectious diseases while fostering a culture of creativity and collaboration within its operations.

Doceree Inc is a healthcare marketing technology company that operates a programmatic physician engagement and advertising platform. Founded in 2019 and based in Parsippany, New Jersey, with an additional office in New Delhi, India, Doceree specializes in connecting pharmaceutical and healthcare brands with healthcare professionals (HCPs). The platform enables targeted advertising and provides data analytics to help clients effectively reach and engage with HCPs in a compliant manner. Utilizing artificial intelligence and data segmentation, Doceree identifies specific HCPs across various digital platforms, including physician networking sites, medical journals, and telemedicine platforms. This approach allows healthcare industry professionals to deliver precise and transparent messaging at scale, catering to the needs of media agencies, pharmaceutical brands, medical device companies, consumer healthcare brands, and hospitals.

K36 Therapeutics is engaged in the development of small molecule therapeutics aimed at treating cancer. The company focuses on translating epigenetic modulation of oncogenic pathways into effective therapies, utilizing technology to create orally bioavailable small molecules and selective inhibitors. This innovative approach enables healthcare professionals to enhance treatment options for cancer patients, addressing the complexities of oncogenic pathways and improving therapeutic outcomes.

BenchSci is a developer of a research intelligence platform that leverages advanced artificial intelligence and machine learning to enhance biomedical discoveries. By translating both closed and open-access data into actionable recommendations, BenchSci enables researchers to optimize experiments, particularly in the area of antibody extraction. This innovative approach allows scientists to conduct more successful experiments efficiently, minimizing resource waste and accelerating drug discovery. The company's technology is utilized by pharmaceutical companies and over 4,300 research centers globally, underscoring its significant impact on the scientific community. BenchSci is backed by notable investors, including F-Prime, Gradient Ventures, and Inovia Capital.

Comanche Biopharma is a biopharmaceutical company focused on developing an investigational small interfering RNA (siRNA) medicine aimed at treating preterm preeclampsia. The company is committed to ensuring that all women and their babies have access to safe and effective therapies for life-threatening complications during pregnancy. Comanche Biopharma's mission emphasizes the importance of evidence-based and affordable solutions, enabling women to receive cost-effective treatments that address the root causes of preeclampsia.

TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution.

Enzene Biosciences is a biotechnology company focused on providing affordable medicines through the development of biosimilars. The company employs advanced technologies, analytics, and a state-of-the-art manufacturing facility to enhance the efficiency of its operations. Enzene specializes in cloning, process development, and novel formulation development, which enables clients to leverage innovative solutions in commercial microbial manufacturing. By fostering strategic global alliances, Enzene aims to broaden the reach of its disruptive technologies and improve healthcare outcomes worldwide. The company is recognized for its strong workplace culture, making it an attractive employer in the biotech sector.

Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.

Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Elucidata Corporation, founded in 2015 and headquartered in New Delhi, India, specializes in accelerating drug discovery through its proprietary SaaS platform, Polly. This platform transforms drug discovery by delivering machine learning-ready biomedical molecular data, supported by a vast repository of over 230,000 multi-omic datasets, with more than 50,000 datasets added monthly. Polly curates this data semi-automatically, enabling data-driven drug discovery teams to integrate proprietary and public biomedical data for machine learning applications. By adhering to the FAIR guidelines, Polly's Data Lakes provide exclusive access to curated multi-omics data, facilitating faster identification of therapeutic assets with a higher likelihood of clinical success. The platform has proven instrumental in detecting validated drug targets across various fields, including immunology, oncology, and metabolomic disorders. Elucidata collaborates with leading organizations such as Pfizer, Agios Pharmaceuticals, and Genentech, as well as over 35 research partners from prominent biopharma companies and research institutions, enhancing decision-making processes in drug research and development.

RIGImmune is a biopharmaceutical company dedicated to developing innovative immune-modulating therapies targeting RNA virus diseases and enhancing antitumor immune responses. The company focuses on creating novel treatments aimed at addressing a wide range of conditions associated with viral infections and certain cancers. Its therapeutic candidates are designed to improve treatment outcomes for viral respiratory infections, serving as adjuvants or boosters for healthcare providers. By advancing its research and development efforts, RIGImmune aims to contribute significantly to the treatment landscape for both viral and oncological diseases.

Peptone Ltd is a London-based company that specializes in developing artificial intelligence solutions aimed at addressing protein development challenges within the biotechnology, biopharmaceutical, and life sciences sectors. Established in 2016, Peptone focuses on the discovery of novel therapeutics, particularly targeting intrinsically disordered proteins. The company offers a range of services, including antibody design and optimization, a comprehensive protein database, and automated thermos-stability engineering. Its proprietary platform, CassandraAI, facilitates in silico protein engineering, enhancing the efficiency of protein development processes. Peptone's advanced protein engineering system addresses complex tasks such as anomaly detection and risk assessment, enabling clients to identify optimal strategies for resolving potential failures. This capability allows users to select suitable commercial partners to produce high-quality molecules more rapidly and cost-effectively than traditional methods employed in the pharmaceutical industry.

Doceree Inc is a healthcare marketing technology company that operates a programmatic physician engagement and advertising platform. Founded in 2019 and based in Parsippany, New Jersey, with an additional office in New Delhi, India, Doceree specializes in connecting pharmaceutical and healthcare brands with healthcare professionals (HCPs). The platform enables targeted advertising and provides data analytics to help clients effectively reach and engage with HCPs in a compliant manner. Utilizing artificial intelligence and data segmentation, Doceree identifies specific HCPs across various digital platforms, including physician networking sites, medical journals, and telemedicine platforms. This approach allows healthcare industry professionals to deliver precise and transparent messaging at scale, catering to the needs of media agencies, pharmaceutical brands, medical device companies, consumer healthcare brands, and hospitals.

Leyden Labs is a biotechnology company focused on developing intranasal products aimed at protecting individuals from respiratory viruses. By targeting commonalities among various viral families, Leyden Labs seeks to provide broad-spectrum protection against multiple strains of viruses, including those in the influenza and coronavirus families. Unlike traditional vaccines that typically address specific variants, Leyden Labs' innovative approach allows for simultaneous protection against a range of viruses, thereby empowering individuals to safeguard their health and prevent the transmission of diseases. The company's team comprises experienced biotechnology professionals and new talent, all committed to advancing solutions that alleviate the impact of respiratory infections on global health.

K36 Therapeutics is engaged in the development of small molecule therapeutics aimed at treating cancer. The company focuses on translating epigenetic modulation of oncogenic pathways into effective therapies, utilizing technology to create orally bioavailable small molecules and selective inhibitors. This innovative approach enables healthcare professionals to enhance treatment options for cancer patients, addressing the complexities of oncogenic pathways and improving therapeutic outcomes.

Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Pediatrix Therapeutics is a pharmaceutical company focused on the field of pediatrics by developing and introducing effective and clinically proven children's medicines to provide Chinese children and families with high-quality and affordable treatment options.

Leyden Labs is a biotechnology company focused on developing intranasal products aimed at protecting individuals from respiratory viruses. By targeting commonalities among various viral families, Leyden Labs seeks to provide broad-spectrum protection against multiple strains of viruses, including those in the influenza and coronavirus families. Unlike traditional vaccines that typically address specific variants, Leyden Labs' innovative approach allows for simultaneous protection against a range of viruses, thereby empowering individuals to safeguard their health and prevent the transmission of diseases. The company's team comprises experienced biotechnology professionals and new talent, all committed to advancing solutions that alleviate the impact of respiratory infections on global health.

Genomics PLC, established in 2014 and headquartered in Oxford, UK, specializes in developing algorithms and software solutions that harness the power of genomics. The company focuses on cancer, microbes, and rare diseases, offering solutions that transform healthcare provisions for governments and providers, de-risk drug development for pharmaceutical clients, enhance diagnoses and treatment options for clinicians, and ensure accurate result processing for research labs and genome analysts. By applying advanced analytics to massive genomic and phenotypic datasets, Genomics PLC aims to lead the genomic transformation of healthcare, revealing the human wiring diagram and setting standards for genomic data utilization.

Yisheng Biopharma Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and marketing of immuno-oncology products and vaccines. Founded in 2002 and headquartered in Beijing, the company operates in China, the United States, Cambodia, and Singapore. Yisheng Biopharma utilizes its novel PIKA immunomodulating technology to enhance immune responses against cancers and infectious diseases. Key products under development include YS-ON-001, an investigational therapy aimed at treating advanced solid tumors, as well as YS-HBV-001, a vaccine for hepatitis B, and a PIKA-based rabies vaccine designed for rapid protection against rabies infection. The company's innovative approach targets multiple immune pathways to improve treatment outcomes.

J-Pharma is a pharmaceutical company focused on developing novel drugs through a human-genomic approach, specifically targeting cell membrane transporters associated with various diseases. The company aims to create selective agents for treating conditions such as cancer by developing anti-cancer drugs and PET diagnostic agents that interact with transporters like LAT1, which are linked to cancer cell growth. J-Pharma's research emphasizes the importance of understanding drug transporters to enhance the pharmacokinetics of new drug candidates. By discovering key transporters within the human body, J-Pharma seeks to advance diagnostic methods and improve treatment options, thereby contributing to global health and enhancing the quality of life for aging populations in industrialized countries.

Citrine Medicine is a rare disease-focused pharmaceutical firm.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

NFlection Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of targeted therapies for rare disorders. Based in Wayne, Pennsylvania, the company primarily addresses conditions such as neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks like keratinocytic epidermal nevi and nevus sebaceous. NFlection specializes in treatments that target the Ras/Raf/MEK/ERK signaling pathway, which is often aberrantly activated in these disorders. One of its notable developments includes a soft mitogen-activated protein kinase (MEK) formulated as a cosmetically elegant gel for topical application, allowing for localized treatment while minimizing systemic side effects typically associated with orally administered MEK inhibitors. Founded in 2014, NFlection Therapeutics aims to improve patient outcomes through innovative therapeutic solutions.

Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.

Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company is advancing inhaled formulations of pirfenidone, specifically AP01, which aims to enhance drug delivery to the lungs while potentially reducing side effects associated with oral treatments. This innovative approach seeks to improve the care and outcomes for patients suffering from these conditions. Established in 2011, Avalyn Pharma operates from its headquarters in Seattle, Washington, and maintains an additional office in San Diego, California. The company was previously known as Genoa Pharmaceuticals, Inc. before rebranding in July 2017.

Rallybio is a clinical-stage biopharmaceutical company focused on developing transformative therapies for patients with severe and rare disorders. Founded in 2018 and based in New Haven, Connecticut, the company is advancing its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a serious condition that can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's portfolio includes a range of promising product candidates targeting rare diseases across various therapeutic areas, including hematology, immuno-inflammation, maternal-fetal health, and metabolic disorders. The company's efforts are supported by a team of experienced professionals with extensive expertise in biopharma research and development.

BenchSci is a developer of a research intelligence platform that leverages advanced artificial intelligence and machine learning to enhance biomedical discoveries. By translating both closed and open-access data into actionable recommendations, BenchSci enables researchers to optimize experiments, particularly in the area of antibody extraction. This innovative approach allows scientists to conduct more successful experiments efficiently, minimizing resource waste and accelerating drug discovery. The company's technology is utilized by pharmaceutical companies and over 4,300 research centers globally, underscoring its significant impact on the scientific community. BenchSci is backed by notable investors, including F-Prime, Gradient Ventures, and Inovia Capital.

Adagene is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology antibodies targeting novel epitopes for cancer treatment. Utilizing its proprietary Smart Antibody Technology, Adagene aims to enhance the success rates of therapeutic antibodies while significantly accelerating the time to market and lowering development costs. The company is dedicated to the research, development, and production of monoclonal antibody drugs, with a pipeline that emphasizes creating therapeutic candidates characterized by functional epitopes and cross-reactivity across species. By transforming the discovery and development processes in the field of antibody-based cancer immunotherapies, Adagene is positioned to make a substantial impact on cancer treatment.

Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.

Sironax is a clinical-stage biotechnology company based in Beijing, China, founded in 2017. The company focuses on developing innovative products and treatments for age-related degenerative diseases, concentrating on mechanisms such as regulated cell death, neuroprotective pathways, and neuroinflammation. By researching apoptosis and other cell death pathways, Sironax aims to create advanced pharmaceuticals that can improve the lives of patients suffering from these conditions. Their goal is to transform the treatment landscape for age-related degenerative diseases, benefiting millions of patients and their families globally.

LunaPBC, Inc. is a Public Benefit Corporation based in San Diego, California, that develops a community-owned platform for genomic and medical research. The company's primary offering, LunaDNA, serves as a knowledge database where individuals can share their health and DNA data to contribute to health research and drive medical discoveries. This platform is designed to benefit both non-profit and for-profit health research projects, facilitating collaboration among pharmaceutical, insurance, and healthcare IT companies. In addition to advancing medical research, LunaPBC allows its members to share in the financial benefits derived from medical breakthroughs, promoting a model of shared community ownership.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

Nocion Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, established in 2017. The company focuses on developing novel therapeutics called "nocions," which are designed to treat conditions associated with neurogenic inflammation. These nocions specifically target activated sensory neurons, entering nociceptors through large-pore channels that open in response to stimulation. This mechanism allows for the selective blocking of sodium channels, providing targeted and sustained relief for serious conditions such as cough, itch, pain, and inflammation. By offering an alternative to traditional small molecule anesthetics, Nocion Therapeutics aims to deliver more effective treatment options for patients suffering from these debilitating symptoms.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for chronic diseases with significant unmet medical needs. Utilizing advanced computational and structure-based technology, the company designs orally available small molecules that aim to overcome the limitations of traditional biologic and peptide drugs. Its lead product candidate, GSBR-1290, is a small molecule agonist targeting the glucagon-like peptide-1 receptor, which is relevant for treating type-2 diabetes and obesity. Additionally, Structure Therapeutics is advancing other oral therapeutics targeting G-protein-coupled receptors for conditions such as pulmonary and cardiovascular diseases, including candidates ANPA-0073 and LTSE-2578. The company combines expertise in drug design and development to create differentiated and effective treatments that can have a profound impact on patient care.

Caplin Point Laboratories Limited is an India-based pharmaceutical company established in 1990, specializing in the development, manufacture, and marketing of generic and branded pharmaceutical products. The company offers a diverse range of products, including tablets, capsules, liquid and lyophilized injections, ophthalmic solutions, ointments, creams, gels, and various specialized formulations. Caplin Point has a significant presence in emerging markets, particularly in Latin America, the Caribbean, and Francophone Africa, holding over 2,000 product licenses worldwide. The company is expanding into regulated markets for injectables with a state-of-the-art manufacturing facility that is compliant with international standards, including approvals from the US FDA and EU-GMP. Additionally, Caplin Point operates QueTenX, an e-commerce platform. The company is headquartered in Chennai, India.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

Genomics PLC, established in 2014 and headquartered in Oxford, UK, specializes in developing algorithms and software solutions that harness the power of genomics. The company focuses on cancer, microbes, and rare diseases, offering solutions that transform healthcare provisions for governments and providers, de-risk drug development for pharmaceutical clients, enhance diagnoses and treatment options for clinicians, and ensure accurate result processing for research labs and genome analysts. By applying advanced analytics to massive genomic and phenotypic datasets, Genomics PLC aims to lead the genomic transformation of healthcare, revealing the human wiring diagram and setting standards for genomic data utilization.

Avidity Biosciences, Inc. is a biotechnology company focused on developing oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These innovative therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. This approach allows Avidity to target previously undruggable tissue and cell types, thereby addressing the underlying genetic drivers of various diseases. The company's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, a rare muscle disease. Additionally, Avidity is advancing multiple programs aimed at treating muscle-related conditions such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Founded in 2012 and based in La Jolla, California, Avidity is also exploring therapeutic applications in immune and other cell types.

PharmEasy is a health tech startup founded in 2015 by Dharmil Sheth, Mikhil Innani, and Dhaval Shah as a subsidiary of Ascent Health. The company operates an online platform that offers a range of healthcare services, including teleconsultation, medicine deliveries, and diagnostic test sample collections. By digitizing the pharmaceutical supply chain, PharmEasy connects patients with local pharmacies and diagnostic centers, facilitating access to essential medicines and healthcare products. This approach aims to make healthcare services more available, affordable, and accessible to patients.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Benchling, Inc. is a cloud-based informatics company that provides a comprehensive platform tailored for life sciences research and development. Its flagship offering allows scientists to design, share, and document experiments through an integrated interface, enhancing collaboration and efficiency. The platform includes Benchling Insights, which enables users to query and visualize structured data, and a Bioregistry system for managing biological entity registrations and inventory such as plasmids and cell strains. Benchling's solutions support a variety of applications, including antibodies, cell therapy, gene therapy, and vaccines, catering to the needs of scientists in biotech, pharmaceutical, academic, and government sectors. Founded in 2012 and headquartered in San Francisco, Benchling aims to streamline the research process from discovery to bioprocessing, facilitating critical R&D decisions with its unified software suite.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Hua Medicine, established in 2009, is a Shanghai-based clinical-stage drug development company. It specializes in therapies for diabetes and central nervous system (CNS) disorders in China. The company's primary focus is Dorzagliatin, an oral drug for Type 2 diabetes, which is in Phase 3 clinical trials, both as a standalone treatment and in combination with metformin. Additionally, Hua Medicine is developing Dorzagliatin in combination with other drugs and mGLUR5 for Parkinson's disease levodopa-induced dyskinesia, both in pre-clinical stages. The company's mission is to address unmet medical needs in China through innovative drug development.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which aims to modify a patient's hematopoietic stem cells to create a personalized treatment through a single administration. Orchard's product portfolio includes Strimvelis, the first gene therapy approved by the European Medicines Agency for adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company is advancing several clinical programs, including OTL-101 for ADA-SCID, OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Additionally, Orchard has a robust preclinical pipeline targeting various mucopolysaccharidosis types. Founded in 2015, Orchard Therapeutics collaborates with leading institutions in the field to enhance its research and development efforts.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Apellis Pharmaceuticals Inc., established in 2009, is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts. The company specializes in developing therapeutic compounds that inhibit the complement system, focusing on autoimmune and inflammatory diseases with high unmet needs. Its lead product candidate, pegcetacoplan, is currently in Phase III trials for treating geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, and in Phase II trials for various kidney and blood disorders. Additionally, Apellis is developing APL-9 for preventing immune system activation during adeno-associated virus administration. The company collaborates with Swedish Orphan Biovitrum AB (publ) to advance pegcetacoplan for treating multiple rare diseases.

Indalo Therapeutics is a preclinical-stage biotechnology company focused on developing innovative therapies for patients afflicted by fibrotic diseases. Founded on significant scientific advancements, the company leverages deep insights into the molecular mechanisms that drive abnormal scarring. By assembling a skilled team of pharmaceutical scientists and industry executives, Indalo aims to address critical unmet medical needs in the field of fibrosis. Its therapeutic approach seeks to not only halt but also potentially reverse the progression of fibrotic conditions, ultimately improving the quality of life for affected individuals.

PlasmaGen Biosciences Pvt. Ltd. is an Indian bio-pharmaceutical company based in Bengaluru, specializing in the manufacture of plasma-derived products and therapies. Established in 2010, the company develops a range of plasma protein therapies, including PlasmaGlob and AlbuMax, which are Normal Human Immunoglobulin formulations for intravenous use. Their product portfolio also includes PlasmaRho-D I.V. for Rho (D) immunization, PlasmaRAB for rabies post-exposure prophylaxis, and PlasmaHep for various hepatitis B-related indications. Additionally, PlasmaGen offers VerBumin for conditions such as hypovolemic shock and plasma exchange dialysis. The company serves a diverse clientele, including clinicians, medical practitioners, corporate hospitals, and government institutions, positioning itself as a key provider of plasma products across various medical fields, including hematology, oncology, and immunology.

VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for dermatological conditions. It offers AMZEEQ, a topical minocycline treatment for non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. The company is advancing its pipeline with FMX103, currently in Phase III clinical trials for moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam under investigation in Phase II trials for moderate-to-severe acne vulgaris. Additionally, VYNE is developing Serlopitant, an oral NK1 receptor antagonist aimed at addressing pruritus associated with prurigo nodularis, as well as exploring therapies for other immuno-inflammatory conditions. Formerly known as Menlo Therapeutics Inc., the company rebranded in September 2020 and is headquartered in Bridgewater, New Jersey.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

Genoa Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of idiopathic pulmonary fibrosis (IPF). It develops GP-101, an aerosol pirfenidone formulation for direct inhalation delivery to the lungs for the treatment of IPF. The company was founded in 2011 and is based in San Diego, California.

Promentis Pharmaceuticals, Inc. is a biopharmaceutical company based in Milwaukee, Wisconsin, established in 2006. The company specializes in developing therapies for neuropsychiatric disorders, with a focus on addressing glutamatergic imbalance and oxidative stress. Promentis is known for its lead compound, SXC-2023, which targets System xc- to treat multiple conditions, including impulse control disorders and obsessive-compulsive disorder. In addition to SXC-2023, Promentis is also working on other compounds aimed at restoring glutamatergic neurotransmission, which is crucial for improving cortical function and managing various psychiatric disorders, including schizophrenia.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company is advancing inhaled formulations of pirfenidone, specifically AP01, which aims to enhance drug delivery to the lungs while potentially reducing side effects associated with oral treatments. This innovative approach seeks to improve the care and outcomes for patients suffering from these conditions. Established in 2011, Avalyn Pharma operates from its headquarters in Seattle, Washington, and maintains an additional office in San Diego, California. The company was previously known as Genoa Pharmaceuticals, Inc. before rebranding in July 2017.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Eywa Pharma is a global generic pharmaceutical company established by experienced professionals from the pharmaceutical industry. The company focuses on manufacturing a wide range of generic medications, ensuring continuous access to essential medicines. Its product offerings span various therapeutic areas and dosage forms, including tablets, capsules, and oral suspensions. Eywa Pharma achieves its goals through a combination of in-house development and strategic in-licensing, enabling it to provide effective and affordable medications to patients and healthcare systems.

Promentis Pharmaceuticals, Inc. is a biopharmaceutical company based in Milwaukee, Wisconsin, established in 2006. The company specializes in developing therapies for neuropsychiatric disorders, with a focus on addressing glutamatergic imbalance and oxidative stress. Promentis is known for its lead compound, SXC-2023, which targets System xc- to treat multiple conditions, including impulse control disorders and obsessive-compulsive disorder. In addition to SXC-2023, Promentis is also working on other compounds aimed at restoring glutamatergic neurotransmission, which is crucial for improving cortical function and managing various psychiatric disorders, including schizophrenia.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which aims to modify a patient's hematopoietic stem cells to create a personalized treatment through a single administration. Orchard's product portfolio includes Strimvelis, the first gene therapy approved by the European Medicines Agency for adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company is advancing several clinical programs, including OTL-101 for ADA-SCID, OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Additionally, Orchard has a robust preclinical pipeline targeting various mucopolysaccharidosis types. Founded in 2015, Orchard Therapeutics collaborates with leading institutions in the field to enhance its research and development efforts.

Hua Medicine, established in 2009, is a Shanghai-based clinical-stage drug development company. It specializes in therapies for diabetes and central nervous system (CNS) disorders in China. The company's primary focus is Dorzagliatin, an oral drug for Type 2 diabetes, which is in Phase 3 clinical trials, both as a standalone treatment and in combination with metformin. Additionally, Hua Medicine is developing Dorzagliatin in combination with other drugs and mGLUR5 for Parkinson's disease levodopa-induced dyskinesia, both in pre-clinical stages. The company's mission is to address unmet medical needs in China through innovative drug development.

Cipla Health is a pharmaceutical company dedicated to developing and commercializing consumer healthcare products. It specializes in creating over-the-counter medicines, including nicotine replacement therapy gum, cough lozenges, immunity booster supplements, and pregnancy care medicines. By focusing on these areas, Cipla Health aims to enhance the healthcare experience for patients and consumers alike. Its commitment to providing accessible and effective healthcare solutions underscores its role in the wellness sector.

Adagene is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology antibodies targeting novel epitopes for cancer treatment. Utilizing its proprietary Smart Antibody Technology, Adagene aims to enhance the success rates of therapeutic antibodies while significantly accelerating the time to market and lowering development costs. The company is dedicated to the research, development, and production of monoclonal antibody drugs, with a pipeline that emphasizes creating therapeutic candidates characterized by functional epitopes and cross-reactivity across species. By transforming the discovery and development processes in the field of antibody-based cancer immunotherapies, Adagene is positioned to make a substantial impact on cancer treatment.

VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for dermatological conditions. It offers AMZEEQ, a topical minocycline treatment for non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. The company is advancing its pipeline with FMX103, currently in Phase III clinical trials for moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam under investigation in Phase II trials for moderate-to-severe acne vulgaris. Additionally, VYNE is developing Serlopitant, an oral NK1 receptor antagonist aimed at addressing pruritus associated with prurigo nodularis, as well as exploring therapies for other immuno-inflammatory conditions. Formerly known as Menlo Therapeutics Inc., the company rebranded in September 2020 and is headquartered in Bridgewater, New Jersey.

Aclaris Therapeutics is a clinical-stage biopharmaceutical company based in the United States, specializing in the development of innovative therapies for dermatological and immuno-inflammatory conditions. Founded by the creators of Vicept Therapeutics, the company is dedicated to addressing significant unmet needs in these fields, focusing on areas where no FDA-approved treatments exist or where treatment options are limited. Aclaris operates primarily in two segments: therapeutics and contract research. The therapeutics segment is engaged in the identification and development of novel drug candidates, while the contract research segment generates revenue through laboratory services. Among its developmental candidates is Zunsemetinib, an oral MK2 inhibitor aimed at treating immuno-inflammatory diseases.

Proteostasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cystic fibrosis and other diseases linked to protein homeostasis. The company’s primary product candidates include PTI-801, a CFTR corrector; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. Proteostasis employs theratyping to tailor treatment strategies based on individual responses to CFTR modulators, regardless of specific mutations. The company collaborates with the Cystic Fibrosis Foundation and Genentech to advance its research and development efforts. Founded in 2006 and based in Boston, Massachusetts, Proteostasis was previously known as Proteoguard, Inc. and rebranded in 2007. In December 2020, it was acquired by Yumanity Therapeutics in a reverse merger transaction.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for women's health infections, particularly bacterial vaginosis (BV). Founded in 2012 and headquartered in Newark, New Jersey, with additional offices in Baltimore, Maryland, and Hamden, Connecticut, the company specializes in the development of its lead product, Solosec (secnidazole), a next-generation 5-nitroimidazole antibiotic designed for a convenient one-dose treatment. This drug offers enhanced pharmacokinetic properties that improve efficacy and tolerability for patients. Symbiomix is supported by prominent healthcare venture capital firms and aims to address the unmet therapeutic needs in the field of gynecologic infections. Since October 2017, it has operated as a subsidiary of Lupin Inc.

Dimension Therapeutics, Inc. is a gene therapy company dedicated to developing innovative treatments for rare and metabolic diseases linked to liver function. Founded in 2013 and based in Cambridge, Massachusetts, the company has established a robust pipeline of gene therapy candidates. Its lead products include DTX101 for hemophilia B and DTX201 for hemophilia A, alongside other programs targeting conditions such as ornithine transcarbamylase deficiency, glycogen storage disease type Ia, phenylketonuria, Wilson disease, and citrullinemia type I. Dimension Therapeutics collaborates with REGENX Biosciences, leveraging its extensive patent portfolio related to NAV vector technology. This partnership enhances Dimension's ability to advance its gene therapy initiatives, particularly in the realm of adeno-associated virus therapeutics. In 2017, Dimension Therapeutics became a subsidiary of Ultragenyx Pharmaceutical Inc.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Innovent Biologics, Inc. is a prominent biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacturing, and commercialization of monoclonal antibodies. The company focuses on therapeutic areas such as oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody approved for treating various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's pipeline includes several important candidates, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma, and IBI-303, an adalimumab biosimilar for autoimmune diseases. The company is also developing innovative therapies for conditions like hypercholesterolemia and various cancers. With a robust portfolio of commercialized products and ongoing strategic collaborations with major pharmaceutical companies, Innovent aims to expand its impact in the global biopharmaceutical landscape. Founded in 2011, Innovent is recognized as one of China's leading biotechnology firms.

Huan Qui Li Kang Technology is an hemostatic product manufacturer.

Adagene is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology antibodies targeting novel epitopes for cancer treatment. Utilizing its proprietary Smart Antibody Technology, Adagene aims to enhance the success rates of therapeutic antibodies while significantly accelerating the time to market and lowering development costs. The company is dedicated to the research, development, and production of monoclonal antibody drugs, with a pipeline that emphasizes creating therapeutic candidates characterized by functional epitopes and cross-reactivity across species. By transforming the discovery and development processes in the field of antibody-based cancer immunotherapies, Adagene is positioned to make a substantial impact on cancer treatment.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Aclaris Therapeutics is a clinical-stage biopharmaceutical company based in the United States, specializing in the development of innovative therapies for dermatological and immuno-inflammatory conditions. Founded by the creators of Vicept Therapeutics, the company is dedicated to addressing significant unmet needs in these fields, focusing on areas where no FDA-approved treatments exist or where treatment options are limited. Aclaris operates primarily in two segments: therapeutics and contract research. The therapeutics segment is engaged in the identification and development of novel drug candidates, while the contract research segment generates revenue through laboratory services. Among its developmental candidates is Zunsemetinib, an oral MK2 inhibitor aimed at treating immuno-inflammatory diseases.

Dimension Therapeutics, Inc. is a gene therapy company dedicated to developing innovative treatments for rare and metabolic diseases linked to liver function. Founded in 2013 and based in Cambridge, Massachusetts, the company has established a robust pipeline of gene therapy candidates. Its lead products include DTX101 for hemophilia B and DTX201 for hemophilia A, alongside other programs targeting conditions such as ornithine transcarbamylase deficiency, glycogen storage disease type Ia, phenylketonuria, Wilson disease, and citrullinemia type I. Dimension Therapeutics collaborates with REGENX Biosciences, leveraging its extensive patent portfolio related to NAV vector technology. This partnership enhances Dimension's ability to advance its gene therapy initiatives, particularly in the realm of adeno-associated virus therapeutics. In 2017, Dimension Therapeutics became a subsidiary of Ultragenyx Pharmaceutical Inc.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing small molecule kinase inhibitors aimed at treating genomically defined cancers and rare diseases. Founded in 2008 and headquartered in Cambridge, Massachusetts, the company focuses on personalized cancer therapies by leveraging its proprietary chemical library and advanced research capabilities. Its key drug candidates include avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, and pralsetinib for RET-altered non-small cell lung cancer and medullary thyroid carcinoma. Additionally, Blueprint Medicines is advancing BLU-263, a KIT inhibitor for mast cell disorders, and fisogatinib for advanced hepatocellular carcinoma, both currently in clinical trials. The company’s innovative approach seeks to address the molecular drivers of cancer and resistance mechanisms, aiming to enhance treatment effectiveness and patient outcomes. Blueprint Medicines has established collaborations with several pharmaceutical companies to further its research and development efforts.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Acacia Pharma Group plc, established in 2007, is a UK-based hospital pharmaceutical company specializing in the discovery, development, and commercialization of products for patients undergoing surgery, invasive procedures, or cancer chemotherapy. Its primary focus is on treating and preventing post-operative nausea and vomiting (PONV) and chemotherapy-induced nausea and vomiting (CINV). Acacia Pharma's lead product, BARHEMSYS, is an intravenous amisulpride for PONV treatment and prophylaxis. Other key products include APD403, an intravenous and oral amisulpride for CINV, and BYFAVO, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic for use in invasive medical procedures. These products primarily serve anesthesiologists and oncologists.